AI-generated summary
The authors report a randomized, double-blind, sham-controlled trial of a home-use dual-wavelength laser device in 64 adults with painful diabetic neuropathy. Active treatment was associated with a larger share of participants reaching at least a 30% foot pain reduction at Week 3 than sham (72.7% vs 32.3%), with short-term relief reported through Week 7.
- Participants
- 64
- Who or what was studied
- Adults with painful diabetic peripheral neuropathy enrolled at four independent U.S. clinical sites
- Wavelengths
- 640, 405 nm
- Limits stated in the abstract
- Assessment ended four weeks after treatment completion, so the findings support only short-term pain relief, and the intervention was used alongside standard care.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on onlinelibrary.wiley.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 405 nm
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Sham, Laser, Wavelength, Neuropathy, Visual analogue scale, Low-level laser therapy, Trial registration, Blinding. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.